Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Atea Pharmaceuticals (AVIR) Non-cash Items (2020 - 2021)

Atea Pharmaceuticals has reported Non-cash Items over the past 2 years, most recently at $31.2 million for Q4 2021.

Quarterly results put Non-cash Items at $31.2 million for Q4 2021, down 88.76% from a year ago — trailing twelve months through Dec 2021 was $31.2 million (down 88.76% YoY), and the annual figure for FY2021 was $31.2 million, up 862.22%.
Non-cash Items for Q4 2021 was $31.2 million at Atea Pharmaceuticals, down from $277.9 million in the prior quarter.
Over the last five years, Non-cash Items for AVIR hit a ceiling of $277.9 million in Q4 2020 and a floor of $22.4 million in Q3 2020.